PARIS, Sept 20 – Over the past few months analysts and experts have been scratching their heads, wondering if leading proteomics company Oxford Glycosciences (LSE: OGS) was losing its edge.

The company appeared to have a poor business plan, a weak drug development pipeline, and little response as companies such as Celera Genomics (NYSE: CRA) and Swiss start-up Geneva Proteomics announced their intentions to dominate the proteomics space.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.